ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
IPO Year: 2019
Exchange: NASDAQ
Website: shockwavemedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/5/2024 | Outperform → Peer Perform | Wolfe Research | |
| 3/27/2024 | $368.00 | Buy | CL King |
| 9/29/2023 | $218.00 | Neutral | UBS |
| 7/10/2023 | $291.00 → $335.00 | Equal-Weight → Overweight | Morgan Stanley |
| 5/30/2023 | $291.00 | Equal-Weight | Morgan Stanley |
| 3/15/2023 | $240.00 | Buy | Needham |
| 12/16/2022 | $285.00 | Buy | Deutsche Bank |
| 12/12/2022 | $300.00 → $235.00 | Overweight → Equal Weight | Wells Fargo |
| 9/6/2022 | $165.00 | Perform → Underperform | Oppenheimer |
| 4/6/2022 | $255.00 | Outperform | Wolfe Research |
15-12G - Shockwave Medical, Inc. (0001642545) (Filer)
S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)
S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)
S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)
S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)
S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)
S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)
POSASR - Shockwave Medical, Inc. (0001642545) (Filer)
8-K - Shockwave Medical, Inc. (0001642545) (Filer)
25-NSE - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G - Shockwave Medical, Inc. (0001642545) (Subject)
SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to
SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three years. These findings confirm the positive, ‘real-world' outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina. Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA. REDUCER-I is a post-market, mu
Enhances Johnson & Johnson's Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech's Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ) and Shockwave Medical, Inc. (NASDAQ:SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit
SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024. Shockwave's management is scheduled for a live fireside chat on Tuesday, April 9, 2024, at 8:45 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the "Investors" section of the company's website at: https://ir.shockwavemedical.com.
Financing and Reinforcement of Board of Directors Builds Momentum in Readiness for the Initiation of the IDE Pivotal Trial Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a € 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The funding round was structured in two separate capital increases which have both been completed. It was co-led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture, and Germany-based TechVision Fund. Other investors include Copar
SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheterGranted new physician and hospital reimbursement for
SANTA CLARA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective February 5, 2024. Renee succeeds Dan Puckett, CFO at Shockwave since 2016, who previously announced his decision to retire. "Renee is a highly skilled and accomplished executive with a proven track record in the medical device and healthcare industries," said Doug Godshall, Chief Executive Officer at Shockwave. "I am thrilled to welcome Renee to Shockwave and look forward to partn
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
4 - Shockwave Medical, Inc. (0001642545) (Issuer)
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to
Enhances Johnson & Johnson's Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech's Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ) and Shockwave Medical, Inc. (NASDAQ:SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335
SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheterGranted new physician and hospital reimbursement for
SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates: Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET)First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET)Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET)Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET) In
SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023. Recent Highlights Recognized revenue of $186.0 million for the third quarter of 2023, representing an increase of 42% from the same period in 2022Announced, priced and closed an offering for convertible debt, with net proceeds of $634.4 millionIntroduced the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual sci
SANTA CLARA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on Monday, November 6, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, November 15, 2023, at 8:45 a.m. Eastern Time, Shockwave Medical management is scheduled to present at the 5th Annual Wolfe Research Healthcare Conference, which is taking place from Tuesday, November 14 - Wednesday, November 15, 2023,
SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023. Recent Highlights Recognized revenue of $180.2 million for the second quarter of 2023, representing an increase of 49% from the same period in 2022As part of the Fiscal Year 2024 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) created three new coronary IVL-specific MS-DRGs, which will become effective October 1, 2023.
SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, August 9, 2023, at 3:30 p.m. Eastern Time, Shockwave Medical management is scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference, which is taking place from Monday, August 7 - Thursday, August 10, 2023 at the Inter
SANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023. Recent Highlights Recognized revenue of $161.1 million for the first quarter of 2023, representing an increase of 72% from the same period in 2022Announced the full U.S. commercial availability of the Shockwave L6 Peripheral IVL Catheter following clearance by the U.S. Food and Drug Administration (FDA)Centers for Medicare & Medicaid Services (CMS), as part of the calendar year 2024 Medi
SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2023 after market close on Monday, May 8, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, May 10, 2023, at 11:20 a.m. Pacific Time, Shockwave Medical management is scheduled for a fireside chat at the BofA Securities 2023 Healthcare Conference, which is taking place from Tuesday, May 9 - Thursday, May 11, 2023 at the Encore Hotel in Las
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit
Financing and Reinforcement of Board of Directors Builds Momentum in Readiness for the Initiation of the IDE Pivotal Trial Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a € 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The funding round was structured in two separate capital increases which have both been completed. It was co-led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture, and Germany-based TechVision Fund. Other investors include Copar
Neptune Medical, a leading innovator in medical technology, is pleased to announce the appointment of Dr. Fred Moll as Chairman of the Board. Dr. Moll, a seasoned entrepreneur and influential figure in the medical technology industry considered to be the father of medical robotics, brings a wealth of experience and expertise to Neptune Medical. Dr. Fred Moll is currently a Managing Partner at Sonder Capital, a venture capital firm focused on investing in breakthrough healthcare technologies. His illustrious career includes founding Intuitive Surgical, a pioneer in robotic-assisted minimally invasive surgery, and Auris Health, which was acquired by Johnson & Johnson. In addition to his r
SANTA CLARA, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Nick West, MA, MD, FRCP, FESC, FACC, has joined the company in the role of Associate Chief Medical Officer. Dr. West will report to Keith Dawkins, MD, Chief Medical Officer, and will be based in Santa Clara, with plans to succeed Dr. Dawkins as CMO in mid-2024. "Dr. West brings to Shockwave a wealth of expertise in the interventional cardiology space," said Dr. Dawkins. "Having known Nick for many years, I am confident that his expertise will be hi
SANTA CLARA, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Chief Financial Officer Dan Puckett plans to retire in the first quarter of 2024. Dan has served as the CFO at Shockwave since he joined the company in 2016. The Board of Directors has initiated a process to identify a successor. Mr. Puckett plans to continue as the Chief Financial Officer until his successor is appointed. "I want to thank Dan for his years of dedication to Shockwave and his contributions to our growth and to our success as an
SANTA CLARA, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Kevin Ballinger has joined its Board of Directors and will serve on Shockwave's Nominating and ESG Committee and the Compensation Committee of the Board. "I am excited to welcome Kevin to our Board of Directors," said Ray Larkin, Chairman of Shockwave Board of Directors. "His background and depth of experience in executive leadership positions in the healthcare industry – and in interventional cardiology in particular – will be invaluable to Shockwav
SANTA CLARA, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Sara Toyloy has joined its Board of Directors and will serve on Shockwave’s Audit Committee. “I am delighted to welcome Sara to our Board of Directors,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “Her background and depth of experience in regulatory and clinical affairs within the medical technology sector are a perfect complement to our current Directors. Sara will be an invaluable resource and addition to Shockwave as we
Wolfe Research downgraded ShockWave Medical from Outperform to Peer Perform
CL King initiated coverage of ShockWave Medical with a rating of Buy and set a new price target of $368.00
UBS initiated coverage of ShockWave Medical with a rating of Neutral and set a new price target of $218.00
Morgan Stanley upgraded ShockWave Medical from Equal-Weight to Overweight and set a new price target of $335.00 from $291.00 previously
Morgan Stanley resumed coverage of ShockWave Medical with a rating of Equal-Weight and set a new price target of $291.00
Needham initiated coverage of ShockWave Medical with a rating of Buy and set a new price target of $240.00
Deutsche Bank initiated coverage of ShockWave Medical with a rating of Buy and set a new price target of $285.00
Wells Fargo downgraded ShockWave Medical from Overweight to Equal Weight and set a new price target of $235.00 from $300.00 previously
Oppenheimer downgraded ShockWave Medical from Perform to Underperform and set a new price target of $165.00
Wolfe Research initiated coverage of ShockWave Medical with a rating of Outperform and set a new price target of $255.00
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400. What Happened: Effective prior to the opening of trading on June 3, Sarepta Therapeutics will join the S&P MidCap 400, replacing Shockwave Medical (NASDAQ:SWAV). Johnson & Johnson (NYSE:JNJ) is expected to acquire Shockwave Medical in a deal that is currently pending final closing conditions. Johnson and Johnson is an S&P 500 constituent. Related Link: Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session How To Buy Sarepta Therapeutics Shares Besides going to a
Sarepta Therapeutics will replace Shockwave Medical in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment. Proteologix’s portfolio includes: PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma. PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. PX128 inhibits IL-13-mediated Th2 skin inflammation, an important disease-driving pathway in A
2024 Financial GuidanceGiven the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE:JNJ), Shockwave Medical is withdrawing its full year 2024 guidance, previously issued on February 15, 2024.
ShockWave Medical (NASDAQ:SWAV) reported quarterly earnings of $1.44 per share which beat the analyst consensus estimate of $0.98 by 46.94 percent. This is a 39.81 percent increase over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $218.81 million which beat the analyst consensus estimate of $207.69 million by 5.35 percent. This is a 35.85 percent increase over sales of $161.07 million the same period last year.
On Tuesday, Johnson & Johnson (NYSE:JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ:SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue of $21.38 billion, almost in line with LSEG’s estimate of $21.4 billion. During the first three months of the year, revenue rose more than 2% YoY. JNJ reported a net income of $5.35 billion, or $2.20
The Shockwave offer that DKI predicted in December happened this week with Johnson & Johnson (NYSE:JNJ)agreeing to pay $335 per share in cash. DKI subscribers celebrated! The PMI came in hot. Don’t want to read the details? The conclusion is “higher for longer”. More insane calls by “experts” crying for lower interest rates in order to help homebuyers ignore the fact that it was low rates that led to this particular housing bubble and the government “help” they want will end up in the sellers’ pockets, not the buyers’ bank accounts. The Congressional Budget Office projects US debt to GDP will be 166% 30 years from now. I’m prepared to make a sizeable bet with anyone reading this that we
Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three years. These findings confirm the positive, ‘real-world' outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina. Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA. REDUCER-I is a post-market, multi-center, observational study designed to collect long-term
CL King analyst Kristen Stewart downgrades Shockwave Medical (NASDAQ:SWAV) from Buy to Neutral.
Leerink Partners analyst Mike Kratky downgrades Shockwave Medical (NASDAQ:SWAV) from Outperform to Market Perform and lowers the price target from $361 to $335.